NOK 15.7
(1.16%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | 1.27 Billion | 1.65 Billion | 1.28 Billion | 129 Million | 188.33 Million | 105.66 Million |
Net Income | 709.15 Million | 1.41 Billion | 894.09 Million | -187.3 Million | 30.69 Million | 147.88 Million |
Depreciation & Amortization | 483.47 Million | 375.5 Million | 247.07 Million | 256.85 Million | 203.1 Million | 63.59 Million |
Deferred income taxes | -968.22 Million | -743.91 Million | -494.65 Million | -514.25 Million | - | - |
Stock-based compensation | 12.98 Million | -7.09 Million | 500 Thousand | 545 Thousand | - | - |
Change in working capital | -263.31 Million | 40.69 Million | 53.75 Million | 46.38 Million | -17.42 Million | 3.93 Million |
Other non-cash items | 1.31 Billion | 572.17 Million | 584.24 Million | 526.77 Million | 378.17 Million | 17.44 Million |
Investing Cash Flow | 379.47 Million | -221.26 Million | -174.32 Million | -172.33 Million | -211.68 Million | -84.49 Million |
Investments in PPE | -19.53 Million | -832.95 Million | -777.76 Million | -143.55 Million | -189.24 Million | -158.14 Million |
Acquisitions | 399.01 Million | 635.89 Million | 646.62 Million | 24.61 Million | - | 54.6 Million |
Investment purchases | -19.53 Million | -24.2 Million | -43.18 Million | -53.39 Million | -22.43 Million | - |
Sales/Maturities of investments | - | - | - | - | - | 19.04 Million |
Other Investing Activities | 19.53 Million | -1.00 | -1.00 | - | -1.00 | 1.00 |
Financing Cash Flow | -1.77 Billion | -1.09 Billion | -498.31 Million | -54.97 Million | 132.44 Million | 119.99 Million |
Debt repayment | -944.7 Million | -284.33 Million | -366.77 Million | -50.84 Million | -78.15 Million | -126.88 Million |
Dividends payments | -621.03 Million | -1.19 Billion | -234.05 Million | -439 Thousand | -10.6 Million | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | 138.27 Million | - | 70.6 Million | - |
Other Financing Activities | -214.21 Million | -187.02 Million | -35.76 Million | -4.13 Million | -5.7 Million | -6.88 Million |
Accounts receivables | - | - | - | - | - | - |
Accounts payables | - | - | - | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | -263.31 Million | 40.69 Million | 53.75 Million | 46.38 Million | -17.42 Million | 3.93 Million |
Cash at beginning of period | 1.37 Billion | 927.72 Million | 290.97 Million | 390.4 Million | 277.38 Million | 120.15 Million |
Cash at end of period | 1.3 Billion | 1.37 Billion | 927.72 Million | 290.97 Million | 390.4 Million | 277.38 Million |
Capital Expenditure | -19.53 Million | -832.95 Million | -777.76 Million | -143.55 Million | -189.24 Million | -158.14 Million |
Effect of forex changes on cash | 47.42 Million | 116.62 Million | 24.36 Million | -1.11 Million | 3.91 Million | 16.06 Million |
Net cash flow / Change in cash | -75.13 Million | 450.14 Million | 636.74 Million | -99.42 Million | 113.01 Million | 157.23 Million |
Free Cash Flow | 1.25 Billion | 817.55 Million | 507.25 Million | -14.55 Million | -915.43 Thousand | -52.48 Million |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 194.09 Million | 143.11 Million | 709.15 Million | 196.79 Million | 157.74 Million | 169.41 Million |
Depreciation & Amortization | 108.32 Million | 111.83 Million | 483.47 Million | 135.41 Million | 111.54 Million | 121.43 Million |
Deferred income taxes | - | - | -968.22 Million | -271.14 Million | -223.4 Million | -243.51 Million |
Stock-based compensation | 10.23 Million | -320 Thousand | 1.27 Million | 320 Thousand | 320 Thousand | 638 Thousand |
Change in working capital | -50.66 Million | 3.06 Million | -263.31 Million | -107.76 Million | -32.43 Million | 8.57 Million |
Other non-cash items | 235.86 Million | 198.96 Million | 1.31 Billion | 394.51 Million | 121.12 Million | 547.01 Million |
Investing Cash Flow | -386.83 Million | 23.11 Million | 379.47 Million | 191.59 Million | 283.84 Million | -85.92 Million |
Investments in PPE | 4.06 | - | -19.53 Million | 205.58 Million | -3.07 Million | -192.48 Million |
Acquisitions | -386.83 Million | 22.5 Million | 399.01 Million | 5.53 Million | 286.91 Million | 106.56 Million |
Investment purchases | - | - | -19.53 Million | -19.53 Million | - | - |
Sales/Maturities of investments | -610.23 Thousand | 610.23 Thousand | - | -1.00 | - | - |
Other Investing Activities | 617.17 Thousand | - | 19.53 Million | 1.00 | -1.00 | - |
Financing Cash Flow | -183.14 Million | -341.64 Million | -1.77 Billion | -652.53 Million | -516.16 Million | -305.17 Million |
Debt repayment | -4.76 Million | -191.19 Million | -944.7 Million | -530.29 Million | -316.02 Million | -83.89 Million |
Dividends payments | -153.8 Million | -150.45 Million | -621.03 Million | -119.17 Million | -144.96 Million | -172.88 Million |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | -24.58 Million | - | -214.21 Million | -3.07 Million | -55.16 Million | -48.38 Million |
Accounts receivables | - | - | - | - | - | - |
Accounts payables | - | - | - | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | -50.66 Million | 3.06 Million | -263.31 Million | -107.76 Million | -32.43 Million | 8.57 Million |
Cash at beginning of period | 1.3 Billion | 1.3 Billion | 1.37 Billion | 1.47 Billion | 1.58 Billion | 1.33 Billion |
Cash at end of period | 981.34 Million | 1.3 Billion | 1.3 Billion | 1.3 Billion | 1.47 Billion | 1.58 Billion |
Capital Expenditure | 4.06 | - | -19.53 Million | 205.58 Million | -3.07 Million | -192.48 Million |
Effect of forex changes on cash | - | - | 47.42 Million | -62.84 Million | -12.3 Million | 38.31 Million |
Net cash flow / Change in cash | -322.39 Million | 1 Million | -75.13 Million | -175.64 Million | -109.73 Million | 250.79 Million |
Free Cash Flow | 270.97 Million | 233.3 Million | 1.25 Billion | 553.72 Million | 131.81 Million | 411.08 Million |
TNGL
EVER
CYTHW
1872
FLOMIC
GILADAFINS